SNDXSyndax Pharmaceuticals Inc同业对比
Syndax Pharmaceuticals Inc 与Pharmaceutical Preparations的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Pharmaceutical Preparations)| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SNDX本股 | $1.6B#7 | — | 104.5x#12 | 9.2x#5 | 627.8%#2 | 10.5%#8 | -158.4%#10 | -1890.2%#14 | -1205.8%#6 | — | 19.8%#9 | — |
| STOK | $1.9B#1 | — | 5.4x#10 | 10.1x#6 | 404.5%#3 | 92.3%#4 | -11.2%#6 | -2.0%#6 | — | — | 27.2%#8 | — |
| SEPN | $1.8B#2 | — | 4.8x#9 | 40.1x#9 | 4174.5%#1 | 31.9%#7 | -148.6%#9 | -12.6%#8 | — | — | 174.3%#4 | — |
| XNCR | $1.8B#3 | — | 3.6x#6 | 14.6x#7 | 13.7%#10 | 60.5%#6 | -141.4%#8 | -18.3%#9 | -31.5%#5 | — | 165.0%#5 | — |
| ANIP | — | 16.4x#3 | — | — | 43.8%#6 | 510.5%#2 | 12.6%#3 | 13.1%#2 | 16.9%#2 | — | -21.0%#12 | — |
| KLRA | $1.7B#4 | — | 1.5x#2 | — | — | — | — | 0.0%#3 | — | — | — | — |
| ETON | $1.6B#5 | — | 35.0x#11 | 20.4x#8 | 104.9%#5 | -20.4%#10 | -1.1%#5 | -9.9%#7 | -1.8%#4 | 4#2 | 224.3%#2 | — |
| ANAB | $1.6B#6 | — | 125.5x#13 | 6.8x#4 | 157.0%#4 | 90.9%#5 | 20.4%#2 | -103.8%#13 | — | — | 178.2%#3 | — |
| KARD | $1.6B#8 | — | 2.5x#3 | — | — | — | — | 0.0%#3 | — | — | — | — |
| INVA | $1.5B#9 | 4.9x#2 | 1.2x#1 | 3.7x#2 | 14.7%#9 | 1059.2%#1 | 39.8%#1 | 22.0%#1 | 14.7%#3 | 5#1 | 8.8%#10 | — |
| BCAX | $1.5B#10 | — | 3.2x#5 | — | — | -102.9%#12 | — | -29.4%#10 | — | — | 106.2%#6 | — |
| XERS | $1.5B#11 | — | — | 5.1x#3 | 43.7%#7 | 101.0%#3 | 8.5%#4 | — | 20.6%#1 | — | 6.5%#11 | — |
| AVLN | $1.5B#12 | — | 3.7x#7 | — | — | — | — | 0.0%#3 | — | — | — | — |
| TYRA | $1.5B#13 | — | 4.1x#8 | — | — | -38.7%#11 | — | -33.9%#11 | — | — | 101.1%#7 | — |
| RARE | $1.4B#14 | — | — | 2.1x#1 | 20.2%#8 | -1.1%#9 | -79.5%#7 | — | — | — | -49.5%#13 | — |
| DMRA | $1.4B#15 | 3.0x#1 | 2.7x#4 | — | — | -878.8%#13 | — | -40.7%#12 | — | — | 675.3%#1 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-09-18。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议